Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

Akili logo

About Akili Stock (NASDAQ:AKLI)

Advanced Chart

Key Stats

Today's Range
$0.43
$0.43
50-Day Range
$0.42
$0.44
52-Week Range
$0.19
$1.25
Volume
N/A
Average Volume
2.20 million shs
Market Capitalization
$34.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

AKLI Stock News Headlines

Stargate could destroy Chinese AI
Stargate is a massive, $500 billion SuperProject involving Microsoft, Nvidia, OpenAI and Oracle, among countless others. It was just announced at the White House in a press conference with President Trump. With plans for 20 data centers occupying 10 million square feet … Stargate is being touted as the largest AI infrastructure undertaking in history.
See More Headlines

AKLI Stock Analysis - Frequently Asked Questions

Akili, Inc. (NASDAQ:AKLI) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.04. The company earned $0.11 million during the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akili investors own include Avino Silver & Gold Mines (ASM), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), NVIDIA (NVDA), P3 Health Partners (PIII), uniQure (QURE) and Rolls-Royce Holdings PLC (RYCEY).

Company Calendar

Last Earnings
5/11/2023
Today
7/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AKLI
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.49 million
Net Margins
-2,492.04%
Pretax Margin
-2,489.32%

Debt

Sales & Book Value

Annual Sales
$1.95 million
Price / Cash Flow
N/A
Book Value
$0.75 per share
Price / Book
0.58

Miscellaneous

Free Float
70,776,000
Market Cap
$34.01 million
Optionable
Optionable
Beta
1.72
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:AKLI) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners